bnt211
biontech
['solid tumor', 'biontech']
 at #esmo2022 showed from its ongoing first-in-human phase 1/2 trial of its car t cell product in patients with r/r advanced solid tumors in testicular cancer patients an orr of 57% &amp; disease control rate of 85%. 
#Medicine| Dir. & Host @MedNewsWeek| Research #Oncology #COVID19 #Immunotherapy #celltherapy #tcellrx #CART #bmtsm| About Me: https://t.co/PZG3UGoJrh